Cargando…
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function(1–3). The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of KMT2A or...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060155/ https://www.ncbi.nlm.nih.gov/pubmed/36922593 http://dx.doi.org/10.1038/s41586-023-05812-3 |
_version_ | 1785017042981617664 |
---|---|
author | Issa, Ghayas C. Aldoss, Ibrahim DiPersio, John Cuglievan, Branko Stone, Richard Arellano, Martha Thirman, Michael J. Patel, Manish R. Dickens, David S. Shenoy, Shalini Shukla, Neerav Kantarjian, Hagop Armstrong, Scott A. Perner, Florian Perry, Jennifer A. Rosen, Galit Bagley, Rebecca G. Meyers, Michael L. Ordentlich, Peter Gu, Yu Kumar, Vinit Smith, Steven McGeehan, Gerard M. Stein, Eytan M. |
author_facet | Issa, Ghayas C. Aldoss, Ibrahim DiPersio, John Cuglievan, Branko Stone, Richard Arellano, Martha Thirman, Michael J. Patel, Manish R. Dickens, David S. Shenoy, Shalini Shukla, Neerav Kantarjian, Hagop Armstrong, Scott A. Perner, Florian Perry, Jennifer A. Rosen, Galit Bagley, Rebecca G. Meyers, Michael L. Ordentlich, Peter Gu, Yu Kumar, Vinit Smith, Steven McGeehan, Gerard M. Stein, Eytan M. |
author_sort | Issa, Ghayas C. |
collection | PubMed |
description | Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function(1–3). The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of KMT2A or mutation of the nucleophosmin 1 gene (NPM1)(4–6). KMT2A rearrangements occur in up to 10% of acute leukaemias and have an adverse prognosis, whereas NPM1 mutations occur in up to 30%, forming the most common genetic alteration in acute myeloid leukaemia(7,8). Here, we describe the results of the first-in-human phase 1 clinical trial investigating revumenib (SNDX-5613), a potent and selective oral inhibitor of the menin–KMT2A interaction, in patients with relapsed or refractory acute leukaemia (ClinicalTrials.gov, NCT04065399). We show that therapy with revumenib was associated with a low frequency of grade 3 or higher treatment-related adverse events and a 30% rate of complete remission or complete remission with partial haematologic recovery (CR/CRh) in the efficacy analysis population. Asymptomatic prolongation of the QT interval on electrocardiography was identified as the only dose-limiting toxicity. Remissions occurred in leukaemias refractory to multiple previous lines of therapy. We demonstrate clearance of residual disease using sensitive clinical assays and identify hallmarks of differentiation into normal haematopoietic cells, including differentiation syndrome. These data establish menin inhibition as a therapeutic strategy for susceptible acute leukaemia subtypes. |
format | Online Article Text |
id | pubmed-10060155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100601552023-03-31 The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia Issa, Ghayas C. Aldoss, Ibrahim DiPersio, John Cuglievan, Branko Stone, Richard Arellano, Martha Thirman, Michael J. Patel, Manish R. Dickens, David S. Shenoy, Shalini Shukla, Neerav Kantarjian, Hagop Armstrong, Scott A. Perner, Florian Perry, Jennifer A. Rosen, Galit Bagley, Rebecca G. Meyers, Michael L. Ordentlich, Peter Gu, Yu Kumar, Vinit Smith, Steven McGeehan, Gerard M. Stein, Eytan M. Nature Article Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function(1–3). The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of KMT2A or mutation of the nucleophosmin 1 gene (NPM1)(4–6). KMT2A rearrangements occur in up to 10% of acute leukaemias and have an adverse prognosis, whereas NPM1 mutations occur in up to 30%, forming the most common genetic alteration in acute myeloid leukaemia(7,8). Here, we describe the results of the first-in-human phase 1 clinical trial investigating revumenib (SNDX-5613), a potent and selective oral inhibitor of the menin–KMT2A interaction, in patients with relapsed or refractory acute leukaemia (ClinicalTrials.gov, NCT04065399). We show that therapy with revumenib was associated with a low frequency of grade 3 or higher treatment-related adverse events and a 30% rate of complete remission or complete remission with partial haematologic recovery (CR/CRh) in the efficacy analysis population. Asymptomatic prolongation of the QT interval on electrocardiography was identified as the only dose-limiting toxicity. Remissions occurred in leukaemias refractory to multiple previous lines of therapy. We demonstrate clearance of residual disease using sensitive clinical assays and identify hallmarks of differentiation into normal haematopoietic cells, including differentiation syndrome. These data establish menin inhibition as a therapeutic strategy for susceptible acute leukaemia subtypes. Nature Publishing Group UK 2023-03-15 2023 /pmc/articles/PMC10060155/ /pubmed/36922593 http://dx.doi.org/10.1038/s41586-023-05812-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Issa, Ghayas C. Aldoss, Ibrahim DiPersio, John Cuglievan, Branko Stone, Richard Arellano, Martha Thirman, Michael J. Patel, Manish R. Dickens, David S. Shenoy, Shalini Shukla, Neerav Kantarjian, Hagop Armstrong, Scott A. Perner, Florian Perry, Jennifer A. Rosen, Galit Bagley, Rebecca G. Meyers, Michael L. Ordentlich, Peter Gu, Yu Kumar, Vinit Smith, Steven McGeehan, Gerard M. Stein, Eytan M. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia |
title | The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia |
title_full | The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia |
title_fullStr | The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia |
title_full_unstemmed | The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia |
title_short | The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia |
title_sort | menin inhibitor revumenib in kmt2a-rearranged or npm1-mutant leukaemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060155/ https://www.ncbi.nlm.nih.gov/pubmed/36922593 http://dx.doi.org/10.1038/s41586-023-05812-3 |
work_keys_str_mv | AT issaghayasc themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT aldossibrahim themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT dipersiojohn themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT cuglievanbranko themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT stonerichard themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT arellanomartha themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT thirmanmichaelj themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT patelmanishr themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT dickensdavids themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT shenoyshalini themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT shuklaneerav themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT kantarjianhagop themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT armstrongscotta themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT pernerflorian themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT perryjennifera themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT rosengalit themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT bagleyrebeccag themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT meyersmichaell themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT ordentlichpeter themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT guyu themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT kumarvinit themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT smithsteven themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT mcgeehangerardm themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT steineytanm themenininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT issaghayasc menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT aldossibrahim menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT dipersiojohn menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT cuglievanbranko menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT stonerichard menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT arellanomartha menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT thirmanmichaelj menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT patelmanishr menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT dickensdavids menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT shenoyshalini menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT shuklaneerav menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT kantarjianhagop menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT armstrongscotta menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT pernerflorian menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT perryjennifera menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT rosengalit menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT bagleyrebeccag menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT meyersmichaell menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT ordentlichpeter menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT guyu menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT kumarvinit menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT smithsteven menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT mcgeehangerardm menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia AT steineytanm menininhibitorrevumenibinkmt2arearrangedornpm1mutantleukaemia |